Cargando…

Discovery of Novel Human Epidermal Growth Factor Receptor-2 Inhibitors by Structure-based Virtual Screening

BACKGROUND: Human epidermal growth factor receptor-2 (HER2) is a trans-membrane receptor like protein, and aberrant signaling of HER2 is implicated in many human cancers, such as ovarian cancer, gastric cancer, and prostate cancer, most notably breast cancer. Moreover, it has been in the spotlight i...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Zheng, Yu, Tian, Sun, Rong, Wang, Shan, Chen, Xiao-Qian, Cheng, Li-Jia, Liu, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809169/
https://www.ncbi.nlm.nih.gov/pubmed/27076751
http://dx.doi.org/10.4103/0973-1296.177912
_version_ 1782423598613397504
author Shi, Zheng
Yu, Tian
Sun, Rong
Wang, Shan
Chen, Xiao-Qian
Cheng, Li-Jia
Liu, Rong
author_facet Shi, Zheng
Yu, Tian
Sun, Rong
Wang, Shan
Chen, Xiao-Qian
Cheng, Li-Jia
Liu, Rong
author_sort Shi, Zheng
collection PubMed
description BACKGROUND: Human epidermal growth factor receptor-2 (HER2) is a trans-membrane receptor like protein, and aberrant signaling of HER2 is implicated in many human cancers, such as ovarian cancer, gastric cancer, and prostate cancer, most notably breast cancer. Moreover, it has been in the spotlight in the recent years as a promising new target for therapy of breast cancer. OBJECTIVE: Since virtual screening has become an integral part of the drug discovery process, it is of great significant to identify novel HER2 inhibitors by structure-based virtual screening. MATERIALS AND METHODS: In this study, we carried out a series of elegant bioinformatics approaches, such as virtual screening and molecular dynamics (MD) simulations to identify HER2 inhibitors from Food and Drug Administration-approved small molecule drug as potential “new use” drugs. Results: Molecular docking identified top 10 potential drugs which showed spectrum affinity to HER2. Moreover, MD simulations suggested that ZINC08214629 (Nonoxynol-9) and ZINC03830276 (Benzonatate) might exert potential inhibitory effects against HER2-targeted anti-breast cancer therapeutics. CONCLUSION: Together, our findings may provide successful application of virtual screening studies in the lead discovery process, and suggest that our discovered small molecules could be effective HER2 inhibitor candidates for further study. SUMMARY: A series of elegant bioinformatics approaches, including virtual screening and molecular dynamics (MD) simulations were took advantage to identify human epidermal growth factor receptor-2 (HER2) inhibitors. Molecular docking recognized top 10 candidate compounds, which showed spectrum affinity to HER2. Further, MD simulations suggested that ZINC08214629 (Nonoxynol-9) and ZINC03830276 (Benzonatate) in candidate compounds were identified as potential “new use” drugs against HER2-targeted anti-breast cancer therapeutics. Abbreviations used: HER2: Human epidermal growth factor receptor-2, FDA: Food and Drug Administration, PDB: Protein Database Bank, RMSDs: Root mean square deviations, SPC: Single point charge, PME: Particle mesh Ewald, NVT: Constant volume, NPT: Constant pressure, RMSF: Root-mean-square fluctuation.
format Online
Article
Text
id pubmed-4809169
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-48091692016-04-13 Discovery of Novel Human Epidermal Growth Factor Receptor-2 Inhibitors by Structure-based Virtual Screening Shi, Zheng Yu, Tian Sun, Rong Wang, Shan Chen, Xiao-Qian Cheng, Li-Jia Liu, Rong Pharmacogn Mag Original Article BACKGROUND: Human epidermal growth factor receptor-2 (HER2) is a trans-membrane receptor like protein, and aberrant signaling of HER2 is implicated in many human cancers, such as ovarian cancer, gastric cancer, and prostate cancer, most notably breast cancer. Moreover, it has been in the spotlight in the recent years as a promising new target for therapy of breast cancer. OBJECTIVE: Since virtual screening has become an integral part of the drug discovery process, it is of great significant to identify novel HER2 inhibitors by structure-based virtual screening. MATERIALS AND METHODS: In this study, we carried out a series of elegant bioinformatics approaches, such as virtual screening and molecular dynamics (MD) simulations to identify HER2 inhibitors from Food and Drug Administration-approved small molecule drug as potential “new use” drugs. Results: Molecular docking identified top 10 potential drugs which showed spectrum affinity to HER2. Moreover, MD simulations suggested that ZINC08214629 (Nonoxynol-9) and ZINC03830276 (Benzonatate) might exert potential inhibitory effects against HER2-targeted anti-breast cancer therapeutics. CONCLUSION: Together, our findings may provide successful application of virtual screening studies in the lead discovery process, and suggest that our discovered small molecules could be effective HER2 inhibitor candidates for further study. SUMMARY: A series of elegant bioinformatics approaches, including virtual screening and molecular dynamics (MD) simulations were took advantage to identify human epidermal growth factor receptor-2 (HER2) inhibitors. Molecular docking recognized top 10 candidate compounds, which showed spectrum affinity to HER2. Further, MD simulations suggested that ZINC08214629 (Nonoxynol-9) and ZINC03830276 (Benzonatate) in candidate compounds were identified as potential “new use” drugs against HER2-targeted anti-breast cancer therapeutics. Abbreviations used: HER2: Human epidermal growth factor receptor-2, FDA: Food and Drug Administration, PDB: Protein Database Bank, RMSDs: Root mean square deviations, SPC: Single point charge, PME: Particle mesh Ewald, NVT: Constant volume, NPT: Constant pressure, RMSF: Root-mean-square fluctuation. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC4809169/ /pubmed/27076751 http://dx.doi.org/10.4103/0973-1296.177912 Text en Copyright: © Pharmacognosy Magazine http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Shi, Zheng
Yu, Tian
Sun, Rong
Wang, Shan
Chen, Xiao-Qian
Cheng, Li-Jia
Liu, Rong
Discovery of Novel Human Epidermal Growth Factor Receptor-2 Inhibitors by Structure-based Virtual Screening
title Discovery of Novel Human Epidermal Growth Factor Receptor-2 Inhibitors by Structure-based Virtual Screening
title_full Discovery of Novel Human Epidermal Growth Factor Receptor-2 Inhibitors by Structure-based Virtual Screening
title_fullStr Discovery of Novel Human Epidermal Growth Factor Receptor-2 Inhibitors by Structure-based Virtual Screening
title_full_unstemmed Discovery of Novel Human Epidermal Growth Factor Receptor-2 Inhibitors by Structure-based Virtual Screening
title_short Discovery of Novel Human Epidermal Growth Factor Receptor-2 Inhibitors by Structure-based Virtual Screening
title_sort discovery of novel human epidermal growth factor receptor-2 inhibitors by structure-based virtual screening
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809169/
https://www.ncbi.nlm.nih.gov/pubmed/27076751
http://dx.doi.org/10.4103/0973-1296.177912
work_keys_str_mv AT shizheng discoveryofnovelhumanepidermalgrowthfactorreceptor2inhibitorsbystructurebasedvirtualscreening
AT yutian discoveryofnovelhumanepidermalgrowthfactorreceptor2inhibitorsbystructurebasedvirtualscreening
AT sunrong discoveryofnovelhumanepidermalgrowthfactorreceptor2inhibitorsbystructurebasedvirtualscreening
AT wangshan discoveryofnovelhumanepidermalgrowthfactorreceptor2inhibitorsbystructurebasedvirtualscreening
AT chenxiaoqian discoveryofnovelhumanepidermalgrowthfactorreceptor2inhibitorsbystructurebasedvirtualscreening
AT chenglijia discoveryofnovelhumanepidermalgrowthfactorreceptor2inhibitorsbystructurebasedvirtualscreening
AT liurong discoveryofnovelhumanepidermalgrowthfactorreceptor2inhibitorsbystructurebasedvirtualscreening